Teva, Alvotech announce FDA approval of interchangeability for SELARSDI

Teva Pharmaceuticals (TEVA), a U.S. affiliate of Teva Pharmaceutical Industries, and Alvotech (ALVO) announced that the U.S. Food and Drug Administration, FDA, has approved SELARSDI injection as interchangeable with the reference biologic Stelara. As of April 30, 2025, SELARSDI is available and interchangeable in all presentations matching the reference product, including the treatment of adults and pediatric psoriatic arthritis and plaque psoriasis, as well as Crohn’s disease, and ulcerative colitis. “The FDA’s confirmation of full interchangeability for SELARSDI is an important development for patients and providers seeking to expand access to this important treatment,” said Thomas Rainey, Senior Vice President, U.S. Biosimilars at Teva. “Teva’s recent launch of two biosimilars – SELARSDI and EPYSQLI – coupled with a rich pipeline of assets expected to launch over the next few years, position Teva to establish a strong leadership position in the growing landscape of biosimilars and to drive growth for the company as it embarks on the next phase of its strategy.”